PhD studentship: BBSRC White Rose DTP - How does DNA damage alter nuclear mRNA export in humans?

Human cells regulate which mRNAs are exported from the nucleus to the cytoplasm in response to DNA damage. In this project you will use computational and molecular biology approaches to provide a genome wide view of how mRNA export changes in response to DNA damage. The project will utilise a range of cutting edge techniques including high throughput DNA sequencing, CRISPR and RNA interference to dissect the biological process. Training in both computational and molecular biology techniques will be provided ensuring the student is fully prepared for 21st century quantitative biology.

For further information contact Professor Stuart Wilson (stuart.wilson@sheffield.ac.uk)

Funding Notes

4 year BBSRC studentship, under the BBSRC White Rose Mechanistic Biology DTP.

We welcome applications from students with first degrees in Biological, Chemical or Physical Sciences. For successful applicants, the studentships would provide funding for tuition fees and living stipend at the current Research Council UK rates (subject to eligibility). Please note that EU citizens must have lived in the UK for at least 3 years to be eligible for full support.

Applicants should have or expect to achieve an undergraduate honours degree at 2.1 or higher in a relevant field

 

References

Viphakone, N., Cumberbatch, M.G., Livingstone, M., Heath, P.R., Dickman, M.J., Catto, J.W. and Wilson, S.A. (2015) Luzp4 defines a new mRNA export pathway in cancer cells. Nuc Acids Res. 43:2353-66

Chang, C., Hautbergue, G., Walsh, M.P., Viphakone, N., Van DijK T., Philipsen, S., Wilson, SA. (2013) Chtop is a component of the dynamic TREX mRNA export complex. EMBO J 32:473-486

Viphakone, N., Hautbergue, G.M., Walsh, M., Chang, C.T., Holland, A., Falco, E.G., Reed, R. and Wilson, S.A. (2012) TREX exposes the RNA binding domain of Nxf1 to enable mRNA export. Nature Communications, 3:1006

Rajan, P.*, Sudbery, I.M.* et al. (2014) Next Generation Sequencing of advanced prostate cancer treated with androgen-deprivation therapy. Eur. Urol. 66:32-9 *joint first authors.